SCHEDULE 13G: Frazier Life Sciences Group Discloses Significant Stake in Jade Biosciences, Inc.
Beneficial Ownership Disclosure
A group of affiliated entities and individuals led by Frazier Life Sciences has disclosed beneficial ownership exceeding 5% in Jade Biosciences, Inc. common stock.
Summary
- Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., and their respective general partners (FHMLSP, L.P., FHMLSP, L.L.C., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., FHMLS X, L.P., FHMLS X, L.L.C., FHMLS XI, L.P., FHMLS XI, L.L.C.) have filed a Schedule 13G.
- Individual reporting persons include James N. Topper, Patrick J. Heron, Albert Cha, James Brush, and Daniel Estes.
- As of April 28, 2025, James N. Topper and Patrick J. Heron each beneficially own 1,772,116 shares of Jade Biosciences, Inc. common stock, representing 5.5% of the class.
- Albert Cha and James Brush each beneficially own 1,736,211 shares, representing 5.4% of the class.
- Daniel Estes beneficially owns 24,008 shares, representing 0.1% of the class.
- The beneficial ownership percentages are calculated based on 32,235,927 shares of Common Stock outstanding on April 28, 2025, as disclosed by the Issuer.
- The reporting persons state that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Jade Biosciences, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a prominent life sciences-focused investment group in Jade Biosciences, Inc., a company operating within the biotechnology sector. Such disclosures provide transparency regarding institutional interest in the company.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling confidence from a specialized investment group.
Key Dates
| Date | Description |
|---|---|
| 04/28/2025 | Date of event which requires the filing of this statement (calculation date for beneficial ownership). |
| 05/05/2025 | Filing date of the Schedule 13G. |
Keywords
Jade Biosciences, Frazier Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Life Sciences
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.